Japan’s Ministry of Health, Labor and Welfare (MHLW) on March 5 unveiled the revised NHI prices for drugs subject to…
HOME > REGULATORY
REGULATORY
- Nusinersen, Tenelia-Canaglu Combo Up for MHLW Panel Review on June 9
May 29, 2017
- Off-Year Revision of NHI Prices “Should Be as Restricted as Possible”: LDP Lawmakers
May 29, 2017
- MOF Panel Calls for Abolishing Price Maintenance Premium, Further Belt-Tightening
May 26, 2017
- MEXT to Probe Company Payments to National Univ. Hospitals: Parliamentary Vice Minister
May 25, 2017
- Suga Tacitly Warns against Watering Down “Annual” Price Revision Plan: CEFP
May 24, 2017
- CEFP Private Members Push Smaller Scope for Price Maintenance Premium, Different Rule for “Me-Too” Meds
May 24, 2017
- Health Minister Pitches Revision to Corporate Eligibility Criteria for Price Maintenance Premium: CEFP
May 24, 2017
- Time Has Arrived to Discuss Formularies at Medical Institutions: MHLW Official
May 23, 2017
- MHLW to Set Deadline to Achieve 80% Generic Goal for “September 2020”
May 23, 2017
- MHLW Council Recognizes Unmet Medical Need for Off-Label Use of 3 Drugs
May 19, 2017
- Maintain Prices for On-Patent Drugs, Off-Year Revisions Should Only Cover Limited Products: FPMAJ
May 19, 2017
- Lawmakers Hear from EFPIA, Say They Didn’t Know Japan Drug Market Would Shrink
May 19, 2017
- Standard Operating Profit Rate for Cost Calculation Pricing Rule Updated to 14.7%: Chuikyo
May 19, 2017
- MHLW Discussing Restrictions on Prescriptions of Codeine-Containing Medicines to Children
May 19, 2017
- JPWA Calls for Off-Year Surveys Covering All Products: Chuikyo Hearing
May 19, 2017
- JGA Calls for Elimination of Price Bracket Grouping Rule for Listed Generics
May 19, 2017
- Global Headquarters Watching Japan, Keep Drug Prices for Patented Period: PhRMA, EFPIA
May 19, 2017
- Social Security Council Subcommittee Negative about Reference Pricing System
May 18, 2017
- FPMAJ, EFPIA See Need to Revisit Cost-Based Pricing Method: Chuikyo
May 18, 2017
- MHLW Advisory Panel to Review Eli Lilly’s JAK Inhibitor Baricitinib on May 30
May 18, 2017
ページ
Japan’s pharmaceutical policy appears to be entering a new phase. The government’s newly approved honebuto policy and growth strategy both…
A few weeks ago, I had coffee with a very talented executive. Let’s call him Kenji. He has a great job, a big salary, and a solid team. But he was unhappy. He felt bored and wanted a new challenge.…
Japan’s Central Social Insurance Medical Council (Chuikyo) on November 5 approved the reimbursement listing for a slate of new medicines,…
The Japanese government on March 7 announced new NHI prices to be applied in the FY2025 drug price revision, revealing…
The Japanese government approved a bill to amend the Pharmaceuticals and Medical Devices (PMD) Act at its Cabinet meeting on…
Japan’s health ministry doled out regulatory approvals for a throng of new medicines on December 27 including Eli Lilly’s obesity…
Japan’s all-important reimbursement policy panel on December 20 approved an outline of drug pricing reforms for FY2024, which enshrines a…